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Background: Transcatheter aortic valve implantation (TAVI in patients with large
aortic annuli (>26mm) can be challenging and may be associated with suboptimal
results, particularly as regards to post-procedural aortic regurgitation (AR). Recently,
Direct Flow Medical (DFM) introduced the 29mm version of their fully repositionable
and retrievable valve to treat aortic annuli measuring 26 to 28.5mm.
Methods: All consecutive patients successfully implanted with a 29mm DFM valve
between December 2013 and May 2014 were retrospectively analyzed in this multi-
center European study. Endpoints were deﬁned according to VARC-2 criteria peri-
procedurally and at 30 days.
Results: A total of 36 high- and extreme-risk patients with severe aortic stenosis were
implanted with a 29mmDFM valve. The mean age of patients was 824.6 years and
90% were males. The average annular diameter and perimeter were 27.41.2mm and
86.83.4mm, respectively. The 29mm DFM was oversized in relation to the native
annulus by 4.9%3.9% by diameter and 5.0%4.0% by perimeter. Implantation of
the 29mm DFM resulted in a reduction of mean transaortic gradient from
41.915.8mmHg to 6.15.1mmHg. Device success was achieved in 97% of patients.
Implantation of a DFM valve was associated with none or trivial AR in 81%, mild AR
in 17%, and moderate AR in 1 (2%) patient. There were no coronary occlusions,
device embolizations, annular rupture or intraprocedural deaths. Complete 30-day
outcomes will be available and presented at the meeting.
Conclusions: The Direct Flow Medical Transcatheter Aortic Valve System was
associated with excellent peri-procedural outcomes and virtually eliminated AR in
patients with aortic stenosis and a large annulus.
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Background: Trans-femoral approach represents the ﬁrst choice of vascular access
for transcatheter aortic valve replacement (TAVR). When not feasible, alternative
approaches such as subclavian or direct ascending aorta (transaortic rout) are used for
self-expandable CoreValve implantation. Aim of this work was to compare the safety
of TAVR with self-expandable valve through these alternative vascular approaches.
Methods: All consecutive patients underwent TAVR with self-expandable CoreValve
prosthesis treated through alternative approach in 4 high volume Italian Centre. Devices
success and combined safety endpoint according to VARC-2 criteria were evaluated.
Results: Among 1049 patients undergoing CoreValve implantation between
September 2007 and February 2014, 242 (23%) have been treated through alternative
access: subclavian (147/242, 61%) and transaortic (95/242, 39%) route because of
peripheral artery disease. Demographic features were quite similar in both groups
except for a higher clinical risk proﬁle [median STS: 10% (IQR 6-14%) vs 6% (IQR
4-12%), p< 0.001] and previous CABG (20% vs 10%, p¼0.021) in transaortic group
compared to subclavian one. Device success was similar in two groups (87% vs 80%,
respectively; p¼0.164). The subclavian group showed higher rate of ﬂuoro time [22
min ( IQR 16-28) vs 17 min (IQR 13-20), p¼0.05] and contrast used (19281 ml vs
14863 ml, p< 0.001). The transaortic group showed a higher incidence of combined
safety end point (27% vs 16%, p¼0.04) mostly driven by a higher rate of acute kidney
injury/stage 2-3 (10% vs 2%, p¼0.01) as well as the length of hospital stay [10 days
(IQR 8-14) vs 8 days (IQR 7-12), p< 0.001]. Compared to subclavian group, the
transaortic had a similar cumulative incidence of survival rate at 30-day (94.6% vs
90%, respectively; p¼0.21).
Conclusions: Compared to subclavian, the transaortic group had higher clinical risk
proﬁle with a higher incidence of combined safety endpoint mostly due to acute
kidney injury/stage 2-3. However, no differences were observed in the device success
and survival rate at 30-day.
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aortic prostheses and is associated with increased mortality. Thus newer devices have
been developed to address this complication. The aim of this study was to assess
performance of second generation Sapien XT (SXT)vs. the third generation Sapien
3(S3)in patients with severe aortic stenosis (AS) undergoing transfemoral aortic valve
implantation (TAVI).
Methods: We analyzed a total of 413 patients undergoing implantation of balloon-
expandable Sapien prosthesis in our institution treated whether with SXT (n¼354) or
the S3 (n¼59).Outcomes were deﬁned according to the standardized Valve Academic
Research Consortium-2 criteria (VARC-2).
Results: Mean age of the TAVI patients was 80.77.6 years, 55% of them were
women and median prosthesis size was 26mm. No differences regarding the baseline
characteristic were observed among both groups. Balloon post-dilatation was per-
formed more frequently after implantation of the SXT than S3 prosthesis (30.8% vs.
8.4% p< 0.01). The incidence of relevant prosthesis regurgitation directly after pro-
cedure and of device failure was signiﬁcantly higher among SXT group (Figure).Conclusions: The third generation balloon-expandable Sapien 3 is safer and more
feasible compared to the second generation Sapien XT valve system.
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Background: Evidence is lacking to support decision making on antiplatelet therapy
following transcatheter aortic valve implantation (TAVI).
Methods: All available studies comparing single with dual antiplatelet treatment
(DAPT) following TAVI were included in a collaborative patient level pooled anal-
ysis. The principal investigator for each trial was approached. Primary endpoint was
deﬁned as the composite of major adverse cerebrovascular and cardiovascular events
(MACCE) at one month, including all-cause mortality, acute coronary syndrome
(ACS), stroke, life threatening or major bleeding.lvular disease - Aortic: TAVR B209
